CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 27 enrolled
Drug / intervention
LCZ696 +3 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03917459
NCT03917459Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction

Novartis Pharmaceuticals·interventional·Posted Apr 17, 2019·Updated Feb 29, 2024

In Brief

A Phase 3 clinical trial evaluating LCZ696, Enalapril matching placebo, and 2 other interventions for Heart Failure and 2 related conditions. Completed, enrolled 27 participants across 13 sites.

Detailed Summary

The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and erectile dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Heart Failure, Systolic, Erectile Dysfunction
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 17, 2019
Enrollment StartApr 16, 2019
Primary CompletionMay 25, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.2 years ago

Interventions

LCZ696drug

sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets

Enalapril matching placebodrug

Placebo to Enalapril 10 mg film-coated tablets

Enalaprildrug

Enalapril 10 mg film-coated tablets

LCZ696 matching placebodrug

Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets